{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,29]],"date-time":"2025-10-29T13:33:25Z","timestamp":1761744805190,"version":"build-2065373602"},"reference-count":14,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2021,3,1]],"date-time":"2021-03-01T00:00:00Z","timestamp":1614556800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,3,1]],"date-time":"2021-03-01T00:00:00Z","timestamp":1614556800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Diabetes & Metabolic Syndrome: Clinical Research & Reviews"],"published-print":{"date-parts":[[2021,3]]},"DOI":"10.1016\/j.dsx.2021.02.011","type":"journal-article","created":{"date-parts":[[2021,2,15]],"date-time":"2021-02-15T12:41:36Z","timestamp":1613392896000},"page":"509-511","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["Dipeptidyl Peptidase-4 inhibitor (Vildagliptin) induced oral mucositis: A case report"],"prefix":"10.1016","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9186-8790","authenticated-orcid":false,"given":"Prasanth","family":"Sankar","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1463-4253","authenticated-orcid":false,"given":"Soumya","family":"Jagadeesan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1687-922X","authenticated-orcid":false,"given":"Waseem N.","family":"Ahmed","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"11","key":"10.1016\/j.dsx.2021.02.011_bib1","doi-asserted-by":"crossref","first-page":"1441","DOI":"10.2165\/11591400-000000000-00000","article-title":"Pharmacology of dipeptidyl peptidase-4 inhibitors","volume":"71","author":"Baetta","year":"2011","journal-title":"Drugs"},{"issue":"2","key":"10.1016\/j.dsx.2021.02.011_bib2","doi-asserted-by":"crossref","first-page":"53","DOI":"10.2337\/diaclin.26.2.53","article-title":"Dipeptidyl peptidase-IV inhibitors: pharmacological profile and clinical use","volume":"26","author":"White","year":"2008","journal-title":"Clin Diabetes"},{"issue":"2","key":"10.1016\/j.dsx.2021.02.011_bib3","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1007\/s00296-013-2710-7","article-title":"DPP4 inhibitor-induced polyarthritis: a report of three cases","volume":"34","author":"Crickx","year":"2014","journal-title":"Rheumatol Int"},{"issue":"6","key":"10.1016\/j.dsx.2021.02.011_bib4","doi-asserted-by":"crossref","first-page":"1052","DOI":"10.1111\/j.1365-2133.1996.tb07941.x","article-title":"Keratinocytes express dipeptidyl-peptidase IV (CD26) in benign and malignant skin diseases","volume":"134","author":"Novelli","year":"1996","journal-title":"Br J Dermatol"},{"issue":"6","key":"10.1016\/j.dsx.2021.02.011_bib5","doi-asserted-by":"crossref","first-page":"1264","DOI":"10.1111\/j.1365-2133.2008.08515.x","article-title":"CD26\/dipeptidyl-peptidase IV in psoriatic skin: upregulation and topographical changes","volume":"158","author":"Van Lingen","year":"2008","journal-title":"Br J Dermatol"},{"issue":"3","key":"10.1016\/j.dsx.2021.02.011_bib6","first-page":"368","article-title":"Dipeptidyl peptidase-IV inhibitors induced bullous pemphigoid: a case report and analysis of cases reported in the European pharmacovigilance database","volume":"41","author":"Garc\u00eda","year":"2016","journal-title":"J\u00a0Clin Pharm Therapeut"},{"key":"10.1016\/j.dsx.2021.02.011_bib7","doi-asserted-by":"crossref","first-page":"1238","DOI":"10.3389\/fimmu.2019.01238","article-title":"Dipeptidyl peptidase-4 inhibitor-associated bullous pemphigoid","volume":"10","author":"Tasanen","year":"2019","journal-title":"Front Immunol"},{"issue":"6","key":"10.1016\/j.dsx.2021.02.011_bib8","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1080\/20786204.2013.10874407","article-title":"Dipeptidyl peptidase-4 inhibitors: their role in the management of type 2 diabetes","volume":"55","author":"Mkele","year":"2013","journal-title":"S\u00a0Afr Fam Pract"},{"issue":"13","key":"10.1016\/j.dsx.2021.02.011_bib9","doi-asserted-by":"crossref","first-page":"1169","DOI":"10.1001\/archinternmed.2010.188","article-title":"Sitagliptin-associated drug allergy: review of spontaneous adverse event reports","volume":"170","author":"Desai","year":"2010","journal-title":"Arch Intern Med"},{"issue":"11","key":"10.1016\/j.dsx.2021.02.011_bib10","doi-asserted-by":"crossref","first-page":"1823","DOI":"10.1345\/aph.1G177","article-title":"Are the Naranjo criteria reliable and valid for determination of adverse drug reactions in the intensive care unit?","volume":"39","author":"Kane-Gill","year":"2005","journal-title":"Ann Pharmacother"},{"issue":"4","key":"10.1016\/j.dsx.2021.02.011_bib11","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1177\/154411130401500405","article-title":"Adverse drug reactions in the orofacial region","volume":"15","author":"Scully","year":"2004","journal-title":"Crit Rev Oral Biol Med"},{"issue":"2","key":"10.1016\/j.dsx.2021.02.011_bib12","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1016\/j.ajoms.2012.09.002","article-title":"Oral ulceration due to a dipeptidyl peptidase-4 inhibitor (sitagliptin): report of a case","volume":"25","author":"Jinbu","year":"2013","journal-title":"Journal of Oral and Maxillofacial Surgery, Medicine, and Pathology"},{"key":"10.1016\/j.dsx.2021.02.011_bib13","article-title":"Linagliptin-associated blistering and ulceration","author":"Psomadakis","year":"2017","journal-title":"Case Reports"},{"year":"2019","series-title":"Diabetes drugs. Day after key diabetes drug goes off patent, 20 generics send prices down by up to 70%","key":"10.1016\/j.dsx.2021.02.011_bib14"}],"container-title":["Diabetes & Metabolic Syndrome: Clinical Research & Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1871402121000345?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1871402121000345?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,29]],"date-time":"2025-10-29T09:13:40Z","timestamp":1761729220000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1871402121000345"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,3]]},"references-count":14,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2021,3]]}},"alternative-id":["S1871402121000345"],"URL":"https:\/\/doi.org\/10.1016\/j.dsx.2021.02.011","relation":{},"ISSN":["1871-4021"],"issn-type":[{"type":"print","value":"1871-4021"}],"subject":[],"published":{"date-parts":[[2021,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Dipeptidyl Peptidase-4 inhibitor (Vildagliptin) induced oral mucositis: A case report","name":"articletitle","label":"Article Title"},{"value":"Diabetes & Metabolic Syndrome: Clinical Research & Reviews","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.dsx.2021.02.011","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Diabetes India. Published by Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}